Objective,2,To observe the clinical efficacy and safety of ultrasound-guided beryllium needle in the treatment of the third lumbar transverse process syndrome （TLVTPS）.,Methods,2,Sixty patients with TLVTPS who were treated in Wangjing Hospital of China Academy of Chinese Medical Sciences from February 2021 to February 2022 were selected and divided into ultrasound group and control group using the random number table method， with 30 cases in each group. The ultrasound group was visualized under ultrasound guidance for beryllium needle treatment； the control group was treated with beryllium needle using the empirical pain point manipulation method. Visual analogue scale （VAS） score， lumbar dysfunction index （ODI） score， lumbar mobility in all directions， treatment times and adverse reactions were compared between the two groups before and after treatment.,Results,2,Before treatment， there was no significant difference in VAS and ODI scores between the two groups （,P,>,0.05）.After 1， 2， 3 and 4 weeks of treatment， the scores of VAS and ODI in both groups decreased （,P,<,0.05），VAS and ODI score in ultrasound group were significantly lower than those in control group （,P,<,0.05）.After treatment， the lumbar mobility of the two groups was increased compared with that before treatment （,P,<,0.05）， and the lumbar mobility of the ultrasound group in all directions after treatment was greater than that of the control group （,P,<,0.05）.In the ultrasound group， there were 1 case， 21 case， 7 case and 1 case after 1， 2， 3 and 4 treatments respectively. There were 0， 6， 17 and 7 cases in the control group treated for 1， 2， 3 and 4 times respectively. The difference between the two groups was statistically significant （,P,<,0.05）. Serious adverse events did not occur in both groups.,Conclusion,2,Ultrasound-guided beryllium needle in the treatment of the third lumbar transverse process syndrome can improve the symptoms of patients with high safety.